MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 207 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,666,156 | -19.5% | 168,900 | +27.3% | 0.38% | -30.0% |
| Q2 2023 | $30,653,700 | +144.7% | 132,700 | +156.7% | 0.54% | +124.4% |
| Q1 2023 | $12,524,842 | -69.2% | 51,700 | -63.1% | 0.24% | -61.9% |
| Q4 2022 | $40,698,275 | +2404.5% | 140,218 | +460.9% | 0.64% | +2786.4% |
| Q3 2022 | $1,625,000 | +81.6% | 25,000 | +100.0% | 0.02% | +83.3% |
| Q2 2022 | $895,000 | -81.8% | 12,500 | -75.0% | 0.01% | -80.0% |
| Q1 2022 | $4,908,000 | +109.1% | 50,000 | +136.8% | 0.06% | +13.2% |
| Q4 2020 | $2,347,000 | -38.5% | 21,114 | -34.4% | 0.05% | -41.1% |
| Q3 2020 | $3,818,000 | -72.2% | 32,162 | -75.4% | 0.09% | -87.0% |
| Q2 2019 | $13,720,000 | -33.5% | 130,900 | -20.5% | 0.69% | -39.2% |
| Q1 2019 | $20,630,000 | +81.6% | 164,700 | +63.4% | 1.14% | +25.4% |
| Q4 2018 | $11,362,000 | +2312.3% | 100,800 | +4481.8% | 0.91% | +3388.5% |
| Q3 2018 | $471,000 | – | 2,200 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthCor Management, L.P. | 902,601 | $100,342,000 | 3.87% |
| L1 Capital Pty Ltd | 113,464 | $12,608,000 | 2.35% |
| Avoro Capital Advisors LLC | 1,225,000 | $136,183,000 | 2.34% |
| Tao Capital Management LP | 51,396 | $5,714,000 | 1.40% |
| ARMISTICE CAPITAL, LLC | 316,000 | $35,130,000 | 1.20% |
| ACUTA CAPITAL PARTNERS, LLC | 32,500 | $3,613,000 | 0.98% |
| Capital Impact Advisors, LLC | 24,351 | $2,707,000 | 0.66% |
| Baker Brothers Advisors | 1,499,213 | $166,668,000 | 0.63% |
| Rock Springs Capital Management LP | 256,768 | $28,545,000 | 0.60% |
| SHIKIAR ASSET MANAGEMENT INC | 12,000 | $1,334,000 | 0.48% |